Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 17;9(10):710.
doi: 10.3390/antibiotics9100710.

Prevalence of Antibiotic-Resistant Pulmonary Tuberculosis in Bangladesh: A Systematic Review and Meta-Analysis

Shoumik Kundu  1 , Mahfuza Marzan  2 , Siew Hua Gan  3 , Md Asiful Islam  4
Affiliations

Prevalence of Antibiotic-Resistant Pulmonary Tuberculosis in Bangladesh: A Systematic Review and Meta-Analysis

Shoumik Kundu et al. Antibiotics (Basel). .

Abstract

Resistance to anti-tuberculosis (anti-TB) antibiotics is a major public health concern for many high-TB burden countries in Asia, including Bangladesh. Therefore, to represent the overall drug-resistance pattern against TB in Bangladesh, a systematic review and meta-analysis was conducted. Databases such as PubMed, Scopus, and Google Scholar were searched to identify studies related to antibiotic-resistant TB. A total of 24 studies covering 13,336 patients with TB were secured and included. The random-effects model was used to calculate the summary estimates. The pooled prevalence of any, mono, multi, poly, and extensive anti-TB antibiotic-resistances were 45.3% [95% CI: 33.5-57.1], 14.3% [95% CI: 11.4-17.2], 22.2% [95% CI: 18.8-25.7], 7.7% [95% CI: 5.6-9.7], and 0.3% [95% CI: 0.0-1.0], respectively. Among any first and second-line anti-TB drugs, isoniazid (35.0%) and cycloserine (44.6%) resistances were the highest, followed by ethambutol (16.2%) and gatifloxacin (0.2%). Any, multi, and poly drug-resistances were higher in retreatment cases compared to the newly diagnosed cases, although mono drug-resistance tended to be higher in newly diagnosed cases (15.7%) than that in retreatment cases (12.5%). The majority (82.6%) of the included studies were of high quality, with most not exhibiting publication bias. Sensitivity analyses confirmed that all outcomes are robust and reliable. It is concluded that resistance to anti-TB drugs in Bangladesh is rampant and fast growing. Therefore, the implementation of a nationwide surveillance system to detect suspected and drug-resistant TB cases, as well as to ensure a more encompassing treatment management by national TB control program, is highly recommended.

Keywords: Bangladesh; antibiotic resistance; epidemiology; meta-analysis; prevalence; pulmonary tuberculosis; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram showing the process of selecting eligible studies.
Figure 2
Figure 2
Funnel plots analyzing publication bias among studies evaluated (A) any-DR, (B) mono-DR, (C) multi-DR, and (D) poly-DR.
Figure 2
Figure 2
Funnel plots analyzing publication bias among studies evaluated (A) any-DR, (B) mono-DR, (C) multi-DR, and (D) poly-DR.
Figure 3
Figure 3
Prevalence of (A) any-DR, (B) mono-DR, (C) multi-DR, (D) poly-DR, and (E) extensive-DR in pulmonary tuberculosis in Bangladesh.
Figure 3
Figure 3
Prevalence of (A) any-DR, (B) mono-DR, (C) multi-DR, (D) poly-DR, and (E) extensive-DR in pulmonary tuberculosis in Bangladesh.
Figure 4
Figure 4
Anti-tuberculosis antibiotic resistance patterns in Bangladesh between 1999 and 2018.
See this image and copyright information in PMC

References

    1. WHO . Global Tuberculosis Report 2019. WHO; Geneva, Switzerland: 2019.
    1. Khatun U.F., Amin R., Islam M., Rob A., Rahim A. Socio-demographic Profile and Drug Sensitivity Pattern of Suspected Drug Resistant Tuberculosis among Patients in Regional Tuberculosis Reference Laboratory (RTRL) of a Tertiary Hospital. J. Med. 2017;18:62–67. doi: 10.3329/jom.v18i2.33680. - DOI
    1. Heysell S.K., Ahmed S., Ferdous S.S., Khan M.S.R., Rahman S.M., Gratz J., Rahman M.T., Mahmud A.M., Houpt E.R., Banu S. Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: Implications for regimen choice. PLoS ONE. 2015;10:e0116795. doi: 10.1371/journal.pone.0116795. - DOI - PMC - PubMed
    1. Aung K., Van Deun A., Declercq E., Sarker M., Das P., Hossain M., Rieder H.L. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int. J. Tuberc. Lung Dis. 2014;18:1180–1187. doi: 10.5588/ijtld.14.0100. - DOI - PubMed
    1. Ahuja S.D., Ashkin D., Avendano M., Banerjee R., Bauer M., Bayona J.N., Becerra M.C., Benedetti A., Burgos M., Centis R. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9:e1001300. doi: 10.1371/annotation/230240bc-bcf3-46b2-9b21-2e6e584f7333. - DOI - PMC - PubMed

LinkOut - more resources